LNTH logo

Lantheus Holdings Inc. (LNTH)

$101.80

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LNTH

Market cap

$6.66B

EPS

4.1

P/E ratio

24

Price to sales

4.2

Dividend yield

--

Beta

0.008064

Price on LNTH

Previous close

$101.72

Today's open

$101.72

Day's range

$101.66 - $101.85

52 week range

$51.80 - $111.86

Profile about LNTH

CEO

Brian A. Markison

Employees

1193

Headquarters

Bedford, MA

Exchange

NASDAQ Global Market

Shares outstanding

65401413

Issue type

Common Stock

LNTH industries and sectors

Healthcare

Pharmaceuticals

News on LNTH

Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer's Disease

BEDFORD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced results from two pivotal Phase 3 studies evaluating the diagnostic performance of the TAUKLARIFY™ (florquinitau F 18 injection) PET imaging, also referred to as MK-6240, which supported FDA use in adults with cognitive impairment being evaluated for Alzheimer's disease to identify patients with neurofibrillary tangle (NFT) pathology.

news source

GlobeNewsWire • Nov 16, 2026

news preview

PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility

Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies WALTHAM, Mass., Nov. 9, 2026 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals, today announced a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH).

news source

PRNewsWire • Nov 9, 2026

news preview

Lantheus Reports Third Quarter 2026 Financial Results

Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025 FDA approves TAUKLARIFY™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer's disease FDA grants final approval for BRAVNETSA™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Announced on August 3, 2026 that the Company has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of the Company in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion BEDFORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect

news source

GlobeNewsWire • Nov 5, 2026

news preview

Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, taking place November 16 – November 19, 2026 in Boston, MA.

news source

GlobeNewsWire • Nov 2, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

BALA CYNWYD, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Oct 6, 2026

news preview

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent

news source

GlobeNewsWire • Sep 30, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Sep 29, 2026

news preview

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer

news source

GlobeNewsWire • Sep 28, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Sep 24, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Lantheus Holdings Inc.

Open an M1 investment account to buy and sell Lantheus Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LNTH on M1